NYSE - Nasdaq Real Time Price USD

Haemonetics Corporation (HAE)

85.07 +1.45 (+1.73%)
At close: April 23 at 4:00 PM EDT
85.07 0.00 (0.00%)
After hours: April 23 at 4:04 PM EDT
Loading Chart for HAE
DELL
  • Previous Close 83.62
  • Open 84.20
  • Bid 50.00 x 900
  • Ask --
  • Day's Range 83.68 - 85.84
  • 52 Week Range 70.74 - 95.26
  • Volume 225,362
  • Avg. Volume 486,020
  • Market Cap (intraday) 4.32B
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) 34.58
  • EPS (TTM) 2.46
  • Earnings Date May 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 105.57

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

www.haemonetics.com

3,034

Full Time Employees

April 01

Fiscal Year Ends

Recent News: HAE

Performance Overview: HAE

Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HAE
0.51%
S&P 500
6.30%

1-Year Return

HAE
0.29%
S&P 500
22.67%

3-Year Return

HAE
25.66%
S&P 500
22.63%

5-Year Return

HAE
2.14%
S&P 500
74.37%

Compare To: HAE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HAE

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    4.32B

  • Enterprise Value

    5.00B

  • Trailing P/E

    34.58

  • Forward P/E

    19.80

  • PEG Ratio (5yr expected)

    1.65

  • Price/Sales (ttm)

    3.44

  • Price/Book (mrq)

    4.58

  • Enterprise Value/Revenue

    3.93

  • Enterprise Value/EBITDA

    18.95

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.97%

  • Return on Assets (ttm)

    6.12%

  • Return on Equity (ttm)

    14.72%

  • Revenue (ttm)

    1.27B

  • Net Income Avi to Common (ttm)

    126.57M

  • Diluted EPS (ttm)

    2.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    195.12M

  • Total Debt/Equity (mrq)

    92.34%

  • Levered Free Cash Flow (ttm)

    117.23M

Research Analysis: HAE

Analyst Price Targets

88.00
105.57 Average
85.07 Current
120.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: HAE

Fair Value

85.07 Current
 

Dividend Score

0 Low
HAE
Sector Avg.
100 High
 

Hiring Score

0 Low
HAE
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
HAE
Sector Avg.
100 High
 

Research Reports: HAE

  • HAE: Lowering target price to $88.00

    HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $88.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • HAE: Raising target price to $91.00

    HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $91.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • HAE: Raising target price to $88.00

    HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $88.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • HAE: Raising target price to $86.00

    HAEMONETICS CORP/MASS has an Investment Rating of HOLD; a target price of $86.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     

People Also Watch